来那替尼治疗HER2突变转移性宫颈癌:2期SUMMIT篮式试验结果
SUMMIT是一项2期篮式试验,评估来那替尼在HER2突变、铂类治疗后进展的持续性/转移性/复发性宫颈癌患者中的疗效与安全性。16例患者接受来那替尼240 mg/日口服,12例可测量患者的确认客观缓解率为25%(95%CI 5.5-57.2%),临床获益率为50%(95%CI 21.1-78.9%),中位无进展生存期7.0个月,中位总生存期16.8个月,未发现新的安全性信号。
要点
- 来那替尼单药在经重度治疗的HER2突变宫颈癌中显示活性,确认客观缓解率25%(95%CI 5.5-57.2%)。
- 临床获益率50%(95%CI 21.1-78.9%),中位无进展生存期7.0个月,中位总生存期16.8个月。
- 最常见不良事件为腹泻(75%)、恶心(44%)和食欲下降(38%),1例(6%)报告3级腹泻,无4级事件。
核心结论
- 来那替尼单药在经重度治疗的HER2突变宫颈癌患者中显示活性,且无新的安全性信号;鉴于铂类治疗失败后有效选择有限,来那替尼值得在该分子定义的患者人群中进一步研究。
研究设计与样本
- SUMMIT是一项2期篮式试验,研究来那替尼在实体瘤中的疗效和安全性。
- 纳入HER2突变、持续性/转移性/复发性宫颈癌且晚期/复发性疾病铂类治疗后进展的患者,接受口服来那替尼240 mg/日,第1周期强制洛哌丁胺预防。
- 主要终点为确认客观缓解率(ORR),次要终点包括缓解持续时间(DOR)、临床获益率(CBR)、无进展生存期(PFS)、总生存期(OS)和安全性。
- 共纳入16例合格患者,其中10例(62.5%)为宫颈内膜腺癌。
主要发现
- 最常见的HER2突变为S310F(占患者的63%)。
- 12例RECIST可测量患者中,3例确认部分缓解(ORR 25%;95%CI 5.5-57.2%);3例疾病稳定≥16周(CBR 50%;95%CI 21.1-78.9%)。
- 缓解者的DOR分别为5.6、5.9和12.3个月。
- 中位PFS为7.0个月(95%CI 0.7-18.3个月);中位OS为16.8个月(95%CI 4.1-NE个月)。
- 最常见不良事件为腹泻(75%)、恶心(44%)和食欲下降(38%);1例患者(6%)报告3级腹泻;无4级事件,无因腹泻停药。
关键数值与推荐
- 来那替尼口服剂量为240 mg/日,第1周期强制洛哌丁胺预防。
- 确认ORR为25%(95%CI 5.5-57.2%),CBR为50%(95%CI 21.1-78.9%)。
- 中位PFS为7.0个月(95%CI 0.7-18.3个月),中位OS为16.8个月(95%CI 4.1-NE个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Somatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active in multiple HER2-mutant cancers. SUMMIT is a phase II basket trial investigating the efficacy and safety of neratinib in solid tumors. METHODS: Patients with HER2-mutant, persistent, metastatic/recurrent cervical cancer with disease progression after platinum-based treatment for advanced/recurrent disease received oral neratinib 240 mg/day with mandatory loperamide prophylaxis during cycle 1. The primary endpoint was confirmed objective response rate (ORR). Secondary endpoints included: response duration (DOR); clinical benefit rate (CBR); progression-free survival (PFS); overall survival (OS); safety. RESULTS: Sixteen eligible patients were enrolled; 10 (62.5%) had endocervical adenocarcinoma. The most common HER2 mutation was S310F (63% of patients). Three of 12 RECIST-measurable patients had confirmed partial responses (ORR 25%; 95%CI 5.5-57.2%); 3 had stable disease ≥16 weeks (CBR 50%; 95%CI 21.1-78.9%). DOR for responders were 5.6, 5.9, and 12.3 months. Median PFS was 7.0 months (95%CI 0.7-18.3 months); median OS was 16.8 months (95%CI 4.1-NE months). Diarrhea (75%), nausea (44%), and decreased appetite (38%) were the most common adverse events. One patient (6%) reported grade 3 diarrhea. There were no grade 4 events, and no diarrhea-related treatment discontinuations. CONCLUSIONS: Neratinib monotherapy showed evidence of activity in heavily pretreated patients with HER2-mutant cervical cancer, with no new safety signals. Given the few effective options for cervical cancer after platinum-based therapy failure, neratinib warrants further investigation in this molecularly defined patient population. TRIAL REGISTRATION NUMBER: NCT01953926 (ClinicalTrials.gov), 2013-002872-42 (EudraCT).
引用
- Oaknin A, Friedman CF, Roman LD, et al. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecol Oncol. 2020. PMID: 32723675. doi:10.1016/j.ygyno.2020.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。